Coronavirus vaccine is a peptide vaccine being developed by Akers Biosciences under a license from Premas Biotech for the treatment of COVID-2019 infections using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.The vaccine candidate is based on the three COVID-19 proteins namely; spike, envelope and membrane. Early research is underway in the US and India.
D-CryptTm platform has capability to express 30 proteins of similar profile to those in the structure of COVID-19 and the technology platform is highly scalable with a robust process.
In March 2020, Akers Biosciencesenters into a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™, and partner with Premas to ultimately seek the US FDA approval. Under the terms of the agreement, Akers is acquiring Cystron Biotech LLC for a $US1 million upfront payment, 6 22 756 shares of common stock or common stock equivalents and a royalty on net sales. In addition, Akers shall make additional payments of cash and stock to the sellers of Cystron Biotech LLC upon the achievement of certain milestones, along with a change of control. Akers is also required to make certain cash payments to Premas upon the achievement of additional milestones. 
Key Development Milestones
In May 2020, Akers Biosciences successfully completed its vaccine prototype based on the transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast. At this time, the company also established manufacturing protocol and commenced large-scale production studies for the vaccine candidate  .